Genentech’s (DNA) for Q2 hit $3 billion, up from $2.2 billion in the same quarter last year. Operating income hit $1.1 billion up from $.75 billion last year.
Big winners in the company’s drug portfolio were Avastin with sales up 33% to $564 million in US product sales and Lucentis, introduced recently with sales of $209 million.
Sales of the company’s No.1 product, Rituxan, were up 11% to $562.
The shares traded flat after hours.
Douglas A. McIntyre
An
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
